The Role of the Global Coalition for Radiotherapy in Political Advocacy for Radiation Therapy as a Cost-Effective and Underfunded Modality Around the World

National Institutes of Health Funding to Support Radiation Oncology Research: A Comparative Trend Analysis Over a Decade, 2011-2021

Purpose

Funding to support radiation oncology discovery and research is essential for advancement in therapeutic strategies to improve outcomes for patients with cancer. We aimed to comprehensively characterize trends in National Institutes of Health (NIH) funding that supports radiation oncology research over time to identify trends, successes, and areas for improvement.

Methods and Materials

We queried the NIH Research Portfolio Online Reporting Tools Expenditures and Results database to identify all awarded grants to support radiation oncology research conducted by principal investigators at academic centers, using 3 individual years as representative samples (2011, 2016, and 2021). Abstracts and keywords for resulting grants were manually searched to identify resulting awards topically related to the field of radiation oncology; principal investigators departmental affiliation was also used as a supplemental method serving as a sensitivity analysis to define radiation oncology-related research. Descriptive statistics were used to describe patterns in funding. χ2 testing was used to assess differences in proportions of categorical variables.

Results

Less than 0.5% of the total NIH budget and < 2% of the total National Cancer Institute budget supported radiation oncology research during the representative study years. There were no significant changes in this allocation pattern over time. A small cohort of institutions held a relatively large proportion of NIH-supported radiation oncology grant funding. Individuals holding PhDs alone received the majority of funding (62%), whereas those with dual-degrees (MD/PhD) held 21% of funding, and those with MD alone were awarded 17% of funding. There was a trend toward an increased proportion of grants awarded to MD/PhDs over time (24% vs 15% in 2021 and 2011, respectively, P = .075).

Conclusions

Despite radiation therapy's essential role in multidisciplinary cancer care, NIH, and National Cancer Institute funding to support radiation oncology research has remained disproportionally low over the last decade. These data may be useful to inform future policy aimed at promoting research advancement in radiation oncology both at the micro (individual) as well as macro (institutional and national) level.

Human Serum Albumin-Coated 10B Enriched Carbon Dots as Targeted "Pilot Light" for Boron Neutron Capture Therapy

Boron neutron capture therapy (BNCT) is a physiologically focused radiation therapy that relies on nuclear capture and fission processes. BNCT is regarded as one of the most promising treatments due to its excellent accuracy, short duration of therapy, and low side effects. The creation of novel boron medicines with high selectivity, ease of delivery, and high boron-effective load is a current research topic. Herein, boron-containing carbon dots (BCDs) and their human serum albumin (HSA) complexes (BCDs-HSA) are designed and synthesized as boron-containing drugs for BNCT. BCDs (10B: 7.1 wt%) and BCDs-HSA exhibited excitation-independent orange fluorescent emission which supported the use of fluorescence imaging for tracking 10B in vivo. The introduction of HSA enabled BCDs-HSA to exhibit good biocompatibility and increased tumor accumulation. The active and passive targeting abilities of BCDs-HSA are explored in detail. Subcutaneous RM-1 tumors and B16-F10 tumors both significantly decrease with BNCT, which consists of injecting BCDs-HSA and then irradiating the area with neutrons. In short, this study provides a novel strategy for the delivery of boron and may broaden the perspectives for the design of boron-containing carbon dots nanomedicine for BNCT.

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

Introduction

Following the Covid-19 pandemic spread, changes in clinical practice were necessary to limit the pandemic diffusion. Also, oncological practice has undergone changes with radiotherapy (RT) treatments playing a key role.Although several experiences have been published, the aim of this review is to summarize the current evidence after 2 years of pandemic to provide useful conclusions for clinicians.

Methods

A Pubmed/MEDLINE and Embase systematic review was conducted. The search strategy was "Covid AND Radiotherapy" and only original articles in the English language were considered.

Results

A total of 2.733 papers were obtained using the mentioned search strategy. After the complete selection process, a total of 281 papers were considered eligible for the analysis of the results.

Discussion

RT has played a key role in Covid-19 pandemic as it has proved more resilient than surgery and chemotherapy. The impact of the accelerated use of hypofractionated RT and telemedicine will make these strategies central also in the post-pandemic period.